MARKET WIRETradingView • 7h ago
ZeroStack Corp. Estimates – NASDAQ:ZSTKTradingView report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.
Why ZSTK Stock dropped -5.12% Today — RQD Quant Desk Flash
$2.78 -5.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.75
ZeroStack Corp. (ZSTK) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $63.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZSTK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.78 (-5.12% 1D, market cap $63.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #949 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZSTK compare to ESYN and COSM in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZSTK?
▼
Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.75 (-1.11%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-14.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZSTK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (25/100 Composite)
🔍 WHY ZSTK SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (40% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (20% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 30.3 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.37-11% Next Q
33
Q2 (-2Q)Grade E$3.89-19.5% Next Q
30
Q3 (-1Q)Grade E$3.13-11.2% Next Q
28
CurrentGrade E$2.78-10.7% Hist 90D α
25
Trajectory: E (33) → E (25)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ZSTK Turnaround Squeeze
While ZSTK currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.37) and Max Pain ($2.92) forces dealer call-delta covering toward $15.79.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZSTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZSTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZSTK Stock dropped -5.12% Today — RQD Quant Desk Flash
ZeroStack Corp. (ZSTK) dropped -5.12% to $2.78, trading at 11% of its 52-week range ($1.32 – $15.04). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($1.32 – $15.04) with RSI-14 at 30.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.78 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 4.6% gross margin and $0 annual free cash flow.
Live ZSTK Headlines & Catalysts
MARKET WIREkalkine.ca • 10h ago
Which of rYojbaba (NASDAQ:RYOJ), Profusa (NASDAQ:PFSA), Beam Global (NASDAQ:BEEM), ZeroStack (NASDAQ:ZSTK) or Presidio Property Trust (NASDAQ:SQFT) Fell 7% to 10% in Pre-Market?kalkine.ca report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 13h ago
ZeroStack Corp. (ZSTK) Stock Price Prediction for 2026, 2030-2040Traders Union report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 17d ago
12 Health Care Stocks Moving In Friday's Pre-Market SessionGainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock moved upwards
MARKET WIREYahoo Finance • 69d ago
Zerostack’s Crypto Holdings Top $1 BillionZerostack’s (NASDAQ: $ZSTK) cryptocurrency holdings have reached $1.06 billion U.S.
MARKET WIREYahoo Finance • 75d ago
Top Midday GainersZeroStack (ZSTK) said Wednesday it entered a $1 billion crypto contribution agreement that will add
MARKET WIREYahoo Finance • 76d ago
ZeroStack Announces Completion of Continuance to TexasDallas, Texas--(Newsfile Corp. - August 18, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) ("ZeroStack" or the "Company"), the first Nasdaq-listed, AI-focused asset management company, today announced that, effective August 18,
MARKET WIREYahoo Finance • 116d ago
ZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical CompaniesToronto, Ontario--(Newsfile Corp. - July 9, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) (the "Company" or "ZeroStack"), the first Nasdaq-listed, AI-focused asset management company, today announced that it has secured pharmac
MARKET WIREYahoo Finance • 213d ago
ZeroStack Inks $107M Deal for 21% of 0G Token SupplyAsset management firm ZeroStack (NASDAQ: $ZSTK) said Tuesday that it agreed to make a massive $107 Millio...
MARKET WIREYahoo Finance • 75d ago
MemeCore Commits $1B in Tokens to ZeroStackZeroStack Corp. (NASDAQ: $ZSTK) has struck a $1 billion crypto contribution deal that would add nearly 926 million ...
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZSTK)
- ✓Walkthrough of ZSTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZSTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.06%📐 HORIZONTAL RANGE
2026-11-02O $2.94H $2.94L $2.78C $2.78VOL 79.4K
SUP: $-1.94SMA50: $4.37SMA200: $5.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZSTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZSTK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZSTK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZSTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZSTK)
Health Care Rank #949 of 1016
⚔️ ESYN vs ZSTK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZSTK vs. ESYN, COSM, NUS, MEDS)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ZeroStack Corp. (ZSTK) ranks #949 by composite RQD confidence (25/100, grade E) and #720 by equity capitalization ($63.9M). Within this direct 5-issuer industry benchmark cohort, ZSTK leads on earnings valuation at N/A trailing P/E, while NUS leads on capital efficiency and profitability with 6.7% ROIC and 69.4% gross margin. NUS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with ZSTK at 25/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZSTK
ACTIVE
ZeroStack Corp. | E | 25/100 | — | 4.6% | -35.0% | -5.12% | $63.9M | Benchmark Subject |
| ESYN EnerSyn Global Inc. | D- | 40/100 | — | 53.0% | -35.0% | -4.37% | $54.4M | /esyn-vs-zstk → |
| COSM Cosmos Health Inc. | E | 29/100 | — | 12.1% | -35.0% | +10.96% | $27.9M | /cosm-vs-zstk → |
| NUS Nu Skin Enterprises Inc. | D+ | 53/100 | — | 69.4% | 6.7% | -0.85% | $228.3M | /nus-vs-zstk → |
| MEDS DataMeds AI Inc. | E | 28/100 | — | -27.5% | -35.0% | -5.42% | $9.8M | /meds-vs-zstk → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001790169In its most recent audited fiscal period (FY2025, filed 2025-12-31), ZeroStack Corp. (ZSTK) reported GAAP revenue of $35.7M (-0.5% vs. FY2024 revenue of $35.9M , and -53.1% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$8.7M, and free cash flow of -$8.8M (-70.4% YoY). On the balance sheet, ZSTK closed FY2025 with $130.2M in total assets against $50.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.7M | $0 | -$8.7M | -$8.8M | $130.2M | $50.8M |
| FY2024 (FY) | 2024-12-31 | $35.9M | -$15.9M | -$5.0M | -$5.2M | $26.2M | $0 |
| FY2023 (FY) | 2023-12-31 | $76.1M | -$57.0M | -$8.4M | -$8.4M | — | — |
3. ZSTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.78 (-5.12% 1D, market cap $63.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #949 in composite RQD confidence.
How does ZSTK compare to ESYN and COSM in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZSTK?
Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZSTK trading relative to its 50-day, 200-day, and 52-week technical levels?
ZSTK last traded at $2.78 (-5.12% on volume of 3,949 shares), positioning the stock -36.38% below its 50-day simple moving average ($4.37) and -46.02% below its 200-day simple moving average ($5.15). Across its 52-week range of $1.32 to $15.04, ZSTK sits at the 10.6% percentile with a 14-day RSI of 30.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.43 to $3.13).
ZSTK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZSTK stock moving today?
Why ZSTK Stock dropped -5.12% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 25/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ZSTK — ZeroStack Corp.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:46:03Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ZSTK scores 25 out of 100, grading E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 4 of 20, reflecting ROIC of -35% and an FCF yield of -13.77%, which indicates the business is not currently generating returns on invested capital or free cash flow to shareholders. Whale/13F flow scores 3 of 20 and insider conviction scores 3 of 20, meaning institutional and insider activity signals are weak. The macro regime fit pillar scores 5 of 20, with a beta of 1.0 and a sector sensitivity profile the rating treats as a drag. The forensic balance sheet pillar scores 10 of 20, citing an Altman Z of 2.5, a Piotroski F of 2 out of 9, and a debt-to-equity ratio of 0.72. For a prospective investor, the upside case rests on a recovery in cash generation and ROIC, which the source data does not show yet; the valuation tradeoff is that the stock trades at a $63.9M market cap with negative cash returns; and the rating's central message is forensic risk, meaning the balance sheet and earnings quality warrant heightened scrutiny before any position is considered.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $35.7M | $-154.7M | $0.0M | N/A | $-8.8M | $5.6M | $50.8M |
| FY 2024 | $35.9M | $-8.9M | $-15.9M | N/A | $-5.2M | $5.2M | $0.0M |
| FY 2023 | $76.1M | $-50.4M | $-57.0M | N/A | $-8.4M | N/A | N/A |
Per the market data, gross margin is 4.6%, operating margin is -60%, net margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, with debt-to-equity at 0.72. Reported revenue declined from $76.1M in FY 2023 to $35.9M in FY 2024 and $35.7M in FY 2025, while FY 2025 operating income was $-154.7M against $-8.9M in FY 2024. Cash moved from $5.2M to $5.6M and debt rose from $0.0M to $50.8M over the FY 2024 to FY 2025 span.
Recent Catalysts & News Wire Analysis
Three headlines reference ZSTK in the news feed, each tagged as market wire with a yellow signal light: a TradingView estimates report, a kalkine.ca pre-market report listing ZSTK among stocks that fell 7% to 10%, and a Traders Union price prediction piece. The summaries are generic and contain no specific fundamental catalyst. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded for this ticker.
Open Questions
- What drove the decline in reported revenue from $76.1M in FY 2023 to $35.7M in FY 2025, and is it expected to stabilize?
- What accounts for the FY 2025 operating loss of $-154.7M relative to the $-8.9M loss in FY 2024?
- How is the $50.8M debt balance structured, including maturities and covenants, given the rise from $0.0M in FY 2024?
- What are the EPS, forward P/E, and EV/EBITDA figures, which are absent from the source data?
- What is the current institutional and insider ownership composition, which the holders section does not provide?
ZSTK Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ZeroStack Corp. (ZSTK) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 7h ago
ZeroStack Corp. Estimates – NASDAQ:ZSTK TradingView report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 10h ago
Which of rYojbaba (NASDAQ:RYOJ), Profusa (NASDAQ:PFSA), Beam Global (NASDAQ:BEEM), ZeroStack (NASDAQ:ZSTK) or Presidio Property Trust (NASDAQ:SQFT) Fell 7% to 10% in Pre-Market? kalkine.ca report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 13h ago
ZeroStack Corp. (ZSTK) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 17d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock moved upwards
🟡 MARKET WIRE Yahoo Finance • 69d ago
Zerostack’s Crypto Holdings Top $1 Billion Zerostack’s (NASDAQ: $ZSTK) cryptocurrency holdings have reached $1.06 billion U.S.
🟡 MARKET WIRE Yahoo Finance • 75d ago
Top Midday Gainers ZeroStack (ZSTK) said Wednesday it entered a $1 billion crypto contribution agreement that will add
🟡 MARKET WIRE Yahoo Finance • 76d ago
ZeroStack Announces Completion of Continuance to Texas Dallas, Texas--(Newsfile Corp. - August 18, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) ("ZeroStack" or the "Company"), the first Nasdaq-listed, AI-focused asset management company, today announced that, effective August 18,
🟡 MARKET WIRE Yahoo Finance • 116d ago
ZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companies Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) (the "Company" or "ZeroStack"), the first Nasdaq-listed, AI-focused asset management company, today announced that it has secured pharmac
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ZSTK Bull vs. Bear Conversation Board — What's Your Call at $2.78?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZSTK 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.58 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ZSTK (E • RQD 25/100) a Buy at $2.93?
Welcome to the ZSTK (ZeroStack Corp.) Roar Pit. Current RQD Composite is 25/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Other Pharmaceuticals. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.20 (-24.9%)
Spot @ $2.93 Pump the brakes on ZSTK — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ZSTK, but look at what you are paying: current EV/EBITDA multiples with 4.6% gross margins. Unless ZeroStack Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $3.75 (+28.0%)
Spot @ $2.93 ZSTK cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ZSTK, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $2.93 (52-wk range $1.32 - $15.04), any beat on forward guidance forces shorts and underweight funds to chase.